Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies. At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies. This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.

[1]  T. Vanhaecke,et al.  Differential Effects of Histone Deacetylase Inhibitors in Tumor and Normal Cells—What Is the Toxicological Relevance? , 2005, Critical reviews in toxicology.

[2]  G. Brosch,et al.  Histone modifications and chromatin dynamics: a focus on filamentous fungi , 2008, FEMS microbiology reviews.

[3]  S. Steinberg,et al.  Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin , 2007, Clinical Cancer Research.

[4]  J. Mariadason.  HDACs and HDAC inhibitors in colon cancer , 2008, Epigenetics.

[5]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[6]  P. Atadja,et al.  A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC) , 2008 .

[7]  Benjamin A. Garcia,et al.  Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation , 2008, Cell.

[8]  C. Pérez-Plasencia,et al.  A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors , 2007, BMC Cancer.

[9]  Karolin Luger,et al.  Nucleosome and chromatin fiber dynamics. , 2005, Current opinion in structural biology.

[10]  H. Hurwitz,et al.  Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors , 2007 .

[11]  K. Camphausen,et al.  Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation , 2004, Clinical Cancer Research.

[12]  P. Atadja,et al.  Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. , 2008, Blood.

[13]  Minoru Yoshida,et al.  From discovery to the coming generation of histone deacetylase inhibitors. , 2003, Current medicinal chemistry.

[14]  W. Stadler,et al.  A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.

[15]  T. Naoe,et al.  Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells , 2000, Japanese journal of cancer research : Gann.

[16]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[17]  K. Chi,et al.  Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer , 2008, Current opinion in supportive and palliative care.

[18]  L. Cuppini,et al.  The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells , 2007, Leukemia.

[19]  M. Carducci,et al.  Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Adimoolam,et al.  HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination , 2007, Proceedings of the National Academy of Sciences.

[21]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[22]  M. Lübbert,et al.  Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells , 2008, Oncogene.

[23]  R. Taulli,et al.  Valproate enhances imatinib‐induced growth arrest and apoptosis in chronic myeloid leukemia cells , 2006, Cancer.

[24]  V. Grégoire,et al.  Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Jin Zhao,et al.  Radiosensitization by the Histone Deacetylase Inhibitor PCI-24781 , 2007, Clinical Cancer Research.

[26]  M. Caraglia,et al.  Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. , 2007, Recent patents on anti-cancer drug discovery.

[27]  A. Zambrano,et al.  Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[28]  M. Jeffers,et al.  Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.

[29]  D. Vigushin,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.

[30]  O. Witt,et al.  Targeting histone deacetylases in neuroblastoma. , 2009, Current pharmaceutical design.

[31]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[32]  Andrew J. Bannister,et al.  Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain , 2001, Nature.

[33]  Wei-Guo Zhu,et al.  The changing face of HDAC inhibitor depsipeptide. , 2009, Current cancer drug targets.

[34]  L. Siu,et al.  First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.

[35]  C. Steidl,et al.  Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.

[36]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Fanucchi,et al.  Recent advances of novel targeted therapy in non-small cell lung cancer , 2009, Journal of hematology & oncology.

[38]  S. Bates,et al.  Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers , 2008 .

[39]  Xiang-Jiao Yang,et al.  Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication , 2005, Molecular and Cellular Biology.

[40]  P. Dent,et al.  Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells , 2008, Clinical Cancer Research.

[41]  Srinivas Annavarapu,et al.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.

[42]  P. Zinzani,et al.  Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL) , 2008 .

[43]  E. Galanis,et al.  Vorinostat in solid and hematologic malignancies , 2009, Journal of hematology & oncology.

[44]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[45]  K. Luger.  Dynamic nucleosomes , 2005, Chromosome Research.

[46]  J. Doroshow,et al.  Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies , 2007, Clinical Cancer Research.

[47]  H. Hess-Stumpp.  Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.

[48]  P. Valagussa,et al.  Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patients , 2008 .

[49]  A. Hagenbeek,et al.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Göttlicher.  Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. , 2004, Annals of hematology.

[51]  R. Schilsky,et al.  Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781 , 2008 .

[52]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[53]  M. Carducci,et al.  Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay , 2008, Clinical Cancer Research.

[54]  O. Politz,et al.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.

[55]  J. Marshall,et al.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. , 2002, Journal of experimental therapeutics & oncology.

[56]  K. Camphausen,et al.  Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid , 2005, International journal of cancer.

[57]  Yue-hua Ma,et al.  New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer , 2009, Journal of hematology & oncology.

[58]  Takeshi Inoue,et al.  Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. , 2002, Biochemical pharmacology.

[59]  D. Hallahan,et al.  Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. , 2006, Cancer research.

[60]  I. Christensen,et al.  Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. , 2008, Cancer biomarkers : section A of Disease markers.

[61]  Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. , 2007, Anti-cancer agents in medicinal chemistry.

[62]  Zhenhao Hua,et al.  Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. , 2010, Urologic oncology.

[63]  V. Ogryzko,et al.  Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.

[64]  L. Siu,et al.  Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor , 2008, Expert opinion on investigational drugs.

[65]  D. Mottet,et al.  Histone deacetylases: target enzymes for cancer therapy , 2007, Clinical & Experimental Metastasis.

[66]  S. Berger.  An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation , 2001, Oncogene.

[67]  P. Pandolfi,et al.  Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.

[68]  Prim B. Singh,et al.  Mammalian chromodomain proteins: their role in genome organisation and expression. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[69]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[70]  E. Sausville,et al.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.

[71]  K. Glaser.  HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.

[72]  Junwu Zhang,et al.  Important roles of reversible acetylation in the function of hematopoietic transcription factors , 2005, Journal of cellular and molecular medicine.

[73]  R. Martell,et al.  Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study , 2008 .

[74]  D. Gandara,et al.  Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  Jun Lu,et al.  HDAC inhibitors: a potential new category of anti-tumor agents. , 2007, Cellular & molecular immunology.

[76]  G. Kouraklis,et al.  Histone deacetylase inhibitors and anticancer therapy. , 2002, Current medicinal chemistry. Anti-cancer agents.

[77]  M. Morris,et al.  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  T. Barbui,et al.  The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). , 2008, Leukemia.

[79]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[80]  I. Christensen,et al.  A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia , 2008, European journal of haematology.

[81]  A. Papavassiliou,et al.  FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities , 2006, Cancer Chemotherapy and Pharmacology.

[82]  P. Atadja,et al.  Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells , 2007, Molecular Cancer Therapeutics.

[83]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[84]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[85]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[86]  K. Bhalla,et al.  A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[87]  K. Luger.  Structure and dynamic behavior of nucleosomes. , 2003, Current opinion in genetics & development.

[88]  Fred Asselbergs,et al.  Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.

[89]  M. Fishman,et al.  Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  S. Hövelmann,et al.  Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial , 2007, British Journal of Cancer.

[91]  M. Minden,et al.  Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. , 2008, Blood.

[92]  C. Wittekind,et al.  Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. , 2008, World journal of gastroenterology.

[93]  P. Marks,et al.  The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.

[94]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[95]  I. Jurisica,et al.  The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells , 2005, Leukemia.

[96]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[97]  Jacques Côté,et al.  The diverse functions of histone acetyltransferase complexes. , 2003, Trends in genetics : TIG.

[98]  M. Ratain,et al.  Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms , 2008 .

[99]  S. Isebaert,et al.  A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[100]  N. Fortunati,et al.  Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. , 2007, Endocrine-related cancer.

[101]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[102]  M. K. Pflum,et al.  Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.

[103]  M. Jung,et al.  Inhibitors of histone deacetylase as new anticancer agents. , 2001, Current medicinal chemistry.

[104]  P. Marks,et al.  Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.

[105]  S. Grant,et al.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.

[106]  C. Schoch,et al.  Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.

[107]  D. Lebwohl,et al.  Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy , 2009, Journal of hematology & oncology.

[108]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[109]  P. Atadja,et al.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. , 2007, Blood.

[110]  Jiang Wu,et al.  Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy , 2008, Medicinal research reviews.

[111]  Hsiang-Yu Lin,et al.  Targeting histone deacetylase in cancer therapy , 2006, Medicinal research reviews.

[112]  W. Yeo,et al.  The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines , 2010, Investigational New Drugs.

[113]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[114]  L. Siu,et al.  Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. , 2008, Expert opinion on investigational drugs.

[115]  P. Marks,et al.  Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. , 2000, Medical and pediatric oncology.

[116]  Isabelle Paquin,et al.  Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. , 2008, Journal of medicinal chemistry.

[117]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  Karl Mechtler,et al.  Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins , 2001, Nature.

[119]  S. Gay,et al.  Epigenetic modifications in rheumatoid arthritis , 2008, Arthritis research & therapy.

[120]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[121]  P. Atadja,et al.  The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. , 2006, Cancer research.

[122]  S. Shankar,et al.  HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.

[123]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  M. Horikoshi,et al.  Simple histone acetylation plays a complex role in the regulation of gene expression. , 2006, Briefings in functional genomics & proteomics.

[125]  H. Mackay,et al.  A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial , 2008 .

[126]  Xiang-Jiao Yang,et al.  Histone deacetylase inhibitors as novel anticancer therapeutics , 2008, Current oncology.

[127]  V. Kiermer,et al.  The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[128]  Suzanne F. Jones,et al.  A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors , 2008 .

[129]  K. Sakamoto,et al.  The aggresome pathway as a target for therapy in hematologic malignancies. , 2008, Molecular genetics and metabolism.

[130]  S. Shankar,et al.  Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. , 2008, Advances in experimental medicine and biology.

[131]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[132]  D. Liu,et al.  Clinical advances in hypomethylating agents targeting epigenetic pathways. , 2010, Current cancer drug targets.

[133]  R. Bociek,et al.  Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) , 2008 .

[134]  Xue-Ru Wu,et al.  The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo , 2007, Journal of Translational Medicine.

[135]  K. Glaser,et al.  Differential protein acetylation induced by novel histone deacetylase inhibitors. , 2004, Biochemical and biophysical research communications.

[136]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[137]  C. Van Waes,et al.  Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 , 2007, Molecular Cancer Therapeutics.

[138]  S. Ishii,et al.  Increased Affinity of c-Myb for CREB-binding Protein (CBP) after CBP-induced Acetylation* , 2001, The Journal of Biological Chemistry.

[139]  M. Rothenberg,et al.  A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas , 2008, Clinical Cancer Research.

[140]  M. Sehested,et al.  Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.

[141]  M. Grever,et al.  The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.

[142]  J. Dancey,et al.  Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  Seon-Young Kim,et al.  Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay , 2009, International Journal of Colorectal Disease.

[144]  P. Atadja,et al.  Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90 , 2007, Clinical Cancer Research.

[145]  R. Kornberg,et al.  Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome , 1999, Cell.